Key Highlights

  • SNO Presentations Scheduled: Data from both NEO100 and NEO212 programs will be presented at the Society for Neuro-Oncology's 31st Annual Meeting in Philadelphia on November 13, 2026.
  • NEO100 Findings: Updated results from a Phase 1/2a study and compassionate use experience focus on IDH1-mutant astrocytoma, with emphasis on durable radiographic remission and prolonged survival.
  • NEO212 Research: A separate presentation will address NEO212's clinical performance in recurrent glioblastoma across multiple patient subgroups.
  • Scale of Ambition: NeOnc is developing a clinical strategy that aims to reach approximately 500 patients across 30 hospitals in three countries.

NeOnc Technologies Holdings(NASDAQ:NTHI), a clinical-stage biopharmaceutical company focused on treatments for hard-to-treat brain cancers, announced on November 2, 2026 that it will present data from two of its investigational programs at the 31st Annual Meeting and Education Day of the Society for Neuro-Oncology in Philadelphia. The presentations are scheduled for November 13 and represent the company's most public scientific showcase to date.

Two Investigational Programs, One Major Scientific Audience

The Society for Neuro-Oncology annual meeting is one of the most important scientific gatherings for researchers, oncologists, and pharmaceutical developers focused on cancers of the central nervous system. Having two separate poster presentations at the event gives NeOnc an opportunity to showcase the breadth of its research pipeline and receive feedback from specialists who work directly with the patient populations the company is targeting.

The first presentation covers NEO100, an intranasal formulation of perillyl alcohol — a naturally occurring compound — delivered directly through the nose to reach the brain. The poster is titled "Durable Radiographic Remission and Prolonged Survival with Intranasal NEO100 in Recurrent WHO Grade III/IV IDH1-Mutant Astrocytoma: Updated Results from a Phase 1/2a Study and Compassionate Use Experience." Thomas C. Chen, M.D., Ph.D., of the University of Southern California and NeOnc, will present the findings.

The title's references to durable radiographic remission and prolonged survival are notable given the historically limited treatment Options available for recurrent IDH1-mutant astrocytoma. However, these are preliminary findings from a Phase 1/2a study, and the data should be interpreted accordingly — as hypothesis-generating rather than conclusive clinical evidence.

NEO212 and the Challenge of Recurrent Glioblastoma

The second presentation addresses NEO212, an oral compound that combines perillyl alcohol with temozolomide, a chemotherapy agent already used in standard glioblastoma treatment. The data focus on patients with recurrent glioblastoma, one of the most common and lethal forms of primary brain cancer.

The poster will present findings across multiple patient subgroups, providing a more granular look at how NEO212 performs in different clinical contexts. Glioblastoma research has been a challenging area for the pharmaceutical industry over decades, with very few agents achieving survival improvements beyond current standard of care.

NEOnc's oral delivery approach for NEO212 represents an attempt to improve patient convenience relative to intravenous chemotherapy, while the perillyl alcohol component is designed to address the blood-brain barrier penetration challenges that complicate many CNS Drug Development programs.

Risks

NeOnc is a clinical-stage company with no approved products and no commercial revenue. Both NEO100 and NEO212 are in early-to-mid clinical development, meaning they face the full gauntlet of clinical trial risk: Phase 2 and Phase 3 data may not replicate the preliminary signals observed in earlier studies. Brain cancer Clinical Trials are particularly challenging because the patient populations are small, the disease course is highly variable, and regulatory endpoints require evidence of meaningful clinical benefit.

The company's ambition to reach 500 patients across 30 hospitals in three countries is an aspirational target that will require substantial Capital and operational infrastructure to execute. Financing risk is significant for clinical-stage companies in this space, particularly given the lengthy timelines and capital-intensive nature of late-stage oncology trials.

What to Watch Next

The November 13 poster presentations at the SNO annual meeting are the most immediate catalyst. Reaction from the neuro-oncology community — both in terms of scientific interest and any published commentary from independent researchers — will be an early signal of how the data are received by the field.

Following the conference, the company's timeline for advancing either program into later-stage trials will be a key area to monitor. Any announcements about new clinical sites, international expansion, or collaboration agreements would indicate progress toward the 500-patient vision.

Sector Context

Brain cancer drug development has historically been one of the most difficult areas in oncology, with a long track record of late-stage clinical failures from both large pharmaceutical companies and smaller developers. The IDH mutation subtype targeted by NEO100 has generated scientific interest because IDH mutations tend to define a more distinct molecular subgroup, potentially improving the precision of targeted approaches.

Intranasal drug delivery is an emerging modality for CNS diseases, attracting interest because it may allow therapeutic agents to bypass the blood-brain barrier more effectively than systemic delivery routes.